US FDA’s Rising First-Cycle Complete Response Rate Draws Congress’ Attention

 
• By Sue Sutter
  
House Appropriations Committee members want a briefing after the FDA's mifepristone review is completed. (Screenshot of House Broadcast)

More from Complete Response Letters

More from User Fees